<DOC>
	<DOCNO>NCT00855608</DOCNO>
	<brief_summary>Direct intravitreal administration medication prefer method treatment uveitis retinal vascular disorder . The eye self contain organ relatively isolated systemic circulation tight blood retinal barrier . Effective intraocular drug level achieve much small amount medication inject intravitreally also result minimal systemic exposure patient . Preliminary study show adalimumab may positive role management uveitis human effective treatment intravitreally animal model . No data publish yet intravitreal use adalimumab human subject .</brief_summary>
	<brief_title>Intravitreal Adalimumab Refractory Diabetic Retinopathy , Choroidal Neovascularization Uveitis : A Pilot Study</brief_title>
	<detailed_description>Abstract Purpose : Our aim study determine efficacy safety intravitreal adalimumab patient active vision threaten uveitis , diabetic macular edema ( DME ) choroidal neovascularization ( CNV ) despite standard treatment ensure safety intravitreal use human rapid onset action . Design : Pilot study , Non-Randomized , Open Label , Single Group Assignment , Safety Study . Participants : 15 eye refractory CNV , DME , uveitis inject intravitreal adalimumab 3 week interval . Patients satisfy inclusion exclusion criterion list end . Methods : Initial treatment consist intravitreal adalimumab injection ( 1.5 mg/ 0.03 mL ) eye patient refractory CNV , DME , uveitis visual acuity less equal 20/70 . Patients follow every 3 week total 6 week . Patients baseline best-corrected visual acuity ( BCVA ) , slit lamp examination , dilate fundus examination , ocular coherence tomography ( OCT ) , fluorescein angiography ( F.A ) , standard electroretinogram ( ERG ) study repeat every visit . If stabilization improvement visual acuity , decrease edema OCT leakage F.A first injection , injection give . The injection delay patient develops acute systemic infection give subsides . If worsen visual acuity first injection , patient shift traditional treatment intravitreal Avastin intravitreal steroid . The paired sample Student t- test , Chi-square test , Pearson correlation ANOVA use analyze mean visual acuity central retinal thickness treatment . Main outcome measure : study response intravitreal adalimumab injection patient different visual acuity baseline measure term improvement visual acuity , shrinkage central retinal thickness , reduction fluid leakage , decrease active inflammatory uveitis . Conclusion : Our goal study efficacy intraocular safety intravitreal adalimumab treatment refractory CNV , DME , uveitis . Background Significance Inflammatory mediator involve pathogenesis diabetic retinopathy , choroidal neovascularization uveitis . Owing propensity visual loss , immunosuppressive treatment form systemic and/or local therapy often required management cystoids macular edema posterior uveitis , diabetes age-related macular degeneration . There change management condition last year , immunomodulatory agent new intraocular delivery system . After new trend intravitreal corticosteroid anti-VEGF , new wave so-called biologic response modifier , predominantly monoclonal antibody direct inflammatory mediator receptor , also cytokine , represent promise generation immunomodulating agent . There rise evidence biologic drug might superior regard anti-inflammatory potential conventional immunosuppressive therapy . Unfortunately , new drug also expensive far . The yearly cost regular weight patient around 20,000 dollar Adalimumab Infliximab . Therefore , may universally available country poorly fund health system individual low economic status . Intravitreal injection anti-VEGF corticosteroid currently standard therapy multitude retinal disease choroidal neovascularization , diabetic maculopathy , proliferative diabetic retinopathy , uveitis . However many patient respond partially develop complication like corticosteroid induce glaucoma cataract . As , look safe new therapy various chorioretinal disorder aim visual improvement . Adalimumab ( Humira ) genetically engineer antibody proinflammatory cytokine , namely , tumor necrosis factor alpha ( TNF-α ) . Adalimumab first member new class TNF antibody compound developed contain exclusively human sequence . Adalimumab ( ADA ) subcutaneously ( SC ) self-administered fully human Ig G1 monoclonal antibody direct tumor necrosis factor alpha ( TNFα ) use intravitreally . We know adalimumab injection eye effective safe people . We perform pilot study determine efficacy safety patient active vision threaten uveitis despite standard immunosuppressive therapy . Unlike infliximab , adalimumab contains nonhuman sequence , make indistinguishable structure function naturally occur human IgG1 . Unlike infliximab , allergic reaction adalimumab appear rare . Subcutaneous Adalimumab currently use treatment systemic inflammatory condition inflammatory disease eye relatively favorable safety profile . However , systemic administration carry risk systemic side effect , case adalimumab severe , increased risk infection , reactivation tuberculosis increase risk lymphoma . Intravitreal injection Adalimumab The eye treat prepared 5 % povidone-iodine solution 1 % lidocaine administer subconjunctival injection 3 4 mm limbus form small bleb intravitreal injection give . Following , 0.03ml adalimumab inject intravitreally use 30 gauge needle par plana 3.5 mm limbus . Twenty minute injection , paracentesis perform case intraocular pressure great 25 mmHg optic nerve head adequately perfuse . By end procedure , eye cover patch one day topical antibiotic ( Ciloxan ) apply 3 time per day 3 day . Potential risk Intravitreal adalimumab never try intravitreal intervention , risk anti-VEGF therapy consist local complication include endophthalmitis ( 0.16 % per injection ) , retinal detachment ( 0.08 % per injection ) , cataract ( 0.07 % per injection ) , subconjuntival hemorrhage mainly related size needle use , uveitis ( 0.09 % per injection ) . Systemic administration carry risk systemic side effect , case adalimumab severe , increased risk infection , reactivation tuberculosis increase risk lymphoma . However , eye self contain organ relatively isolated systemic circulation tight blood retinal barrier , unknown much amount drug inject intravitreally get reabsorb systemically . Post-injection follow-up Patients examine every 3 week measure BCVA along slit-lamp examination anterior segment , dilate fundus examination , OCT , F.A , ERG . If patient develop decrease visual acuity least five letter vision post first injection , he/she shift traditional treatment intravitreal avastin intravitreal steroid . Else , vision stable , patient continue treatment The total follow-up period every patient 6 week . Main outcome Our goal study efficacy intraocular safety intravitreal adalimumab treatment refractory CNV , DME , uveitis ensure rapid onset action . The main outcome measure proportion patient lose few 15 letter ( 3 line ) BCVA score 6 week compare baseline . Secondary visual acuity endpoint 6 week include 1 ) mean change baseline BCVA score ; 2 ) proportion patient gain ≥15 letter BCVA ; 3 ) proportion patient Snellen visual acuity 20/70 bad compare baseline . Other secondary endpoint include effect adalimumab central retinal thickness ( CRT ) assess OCT lesion size assess F.A . Literature Cited 1-Intravitreal Adalimumab 1A- Manzano et al evaluate ocular toxicity escalate dos intravitreous adalimumab ( Humira ) rabbit eye . Slit-lamp biomicroscopy fundoscopy carry baseline , day 1 , 7 14 follow intravitreous injection . Escalating dos intravitreous adalimumab rabbit eye cause detectable functional structural ocular toxicity dose 0.50 mg. Administration 1.0 mg 0.1 ml associate inflammatory reaction . ( Manzano RP et al Ocular toxicity intravitreous adalimumab ( Humira ) rabbit . Graefes Arch Clin Exp Ophthalmol . 2008 Jun ; 246 ( 6 ) :907-11 ) . 1B- Use intravitreal etanercept , another TNF antagonist human , improvement vision diabetic macular edema ( Tsilimbaris MK , et al . The use intravitreal etanercept diabetic macular oedema Semin Ophthalmol 2007 Apr-Jun ; 22 ( 2 ) :75-9 ) . 1C-Intravitreal Administration Anti-Tumor Necrosis Factor Agent Infliximab Neovascular Age-related Macular Degeneration.Theodossiadis PG , Liarakos VS , Sfikakis PP , Vergados IA , Theodossiadis GP.Am J Ophthalmol . 2009 Feb 9 . [ Epub ahead print ]</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 17 year Patients active choroidal neovascularization , diabetic retinopathy , uveitis study eye improve conventional therapy Best correct visual acuity 20/70 less . Are participate another clinical study require follow examination Have receive experimental drug within 12 week prior enrollment Are unwilling unable follow comply studyrelated procedure Inability obtain photograph , fluorescein angiography , optical coherence tomography document CNV , e.g . due medium opacity , allergy fluorescein dye lack venous access Aphakia pseudophakia absence posterior capsule ( unless result yttrium aluminum garner [ YAG ] ) posterior capsulotomy ) Within two month prior screen , intraocular surgery ( include cataract surgery ) study eye Within 1 month prior screen YAG laser study eye Have intravitreal anti VEGF intravitreal steroid last 6 week Have previous par plana vitrectomy study eye Are pregnant try become pregnant Any condition investigator believe would pose significant hazard subject investigational therapy initiate</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>choroidal neovascularization</keyword>
	<keyword>diabetic retinopathy</keyword>
	<keyword>uveitis</keyword>
	<keyword>refractory case uveitis</keyword>
</DOC>